


## RELIANCE EXPERIENCE THROUGH ASEAN JOINT ASSESSMENT - INDONESIA

Christine Siagian Director of Drug Registration Badan Pengawas Obat dan Makanan / BPOM (Indonesian FDA)

> 13<sup>th</sup> Asia Partnership Conference of Pharmaceutical Associations Japan, April 23<sup>rd</sup> 2024




#### **RELIANCE MECHANISM IN INDONESIA**



The evaluation process of 120 WD

- Medicines are approved at proposed reference country
- Applicant provides full assessment report (unredacted) from at least 1 regulatory agency of the reference country with well-established evaluation system

#### Sovereignty



## **Regulation of Reliance System in Indonesia**



Not applicable for drugs that require The criteria of reference country : specific evaluation regarding differences established evaluation Has an in disease patterns, resistance patterns system. and/or national program policies **Regulation of** Has Public Assessment Report • (PAR) in English. The Has become a reference country to Chairperson of • Antibiotic other countries. The Indonesian **FDA Number 24** Year 2017 and istralian Governmen **Department of Health** UROPEAN MEDICINES AGENCY its addendum Theraneutic Goods Administrat Number 15 Medicines & Healthcare Health Canada products Year 2019 Unredacted full assessment report Regulatory Agency from the reference country

- The CMC (chemistry, manufacturing, control) should be the same with that of approved in reference country
- Approval within the last 5 years in the proposed reference country.

Applicable for new drug registration and registration of major variations for new indication/new posology of Biological Products and New Chemical Drugs



## **Joint Assessment**



Joint assessment is a formal procedure in which the same application is simultaneously submitted to all participating National Regulatory Authorities (NRAs).



Assessment is carried out by all participating NRAs and then a joint assessment report is prepared.



At the end of the process, the final decision is then taken by each individual NRA through their regular decision-making process

# **Joint Assessment Experiences in BPOM**



1.Dengvaxia in 2015 2.nOPV2 in 2020



1.Qdenga (Indonesian FDA as observer)

2.Perjeta, variation on MCB change, in 2024 (on going)



1.Pyramax in 2018 2.Ocrevus in 2023



## **ASEAN JACG: Pyramax and Ocrevus**

### 2018 Pilot Project

Evaluation on Malaria Drug (Pyramax, containing artesunate and pyronaridine)

## 2023

- Evaluation on Ocrevus containing Ocrelizumab.
- Ocrevus was approved by Indonesian FDA on January 22, 2024 (82 working days from required 300 working days)


#### **Approved indication** by The Indonesian FDA:

Ocrevus is indicated for the treatment of adult patients with relapsing forms of multiple (RMS) with active sclerosis disease defined by clinical or imaging features (see section 5.1).

Ocrevus is indicated for the treatment of adult patients with primary early progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity (see section 5.1).




#### **Multiple Sclerosis**



Nerve affected by MS



#### Our Experience on ASEAN JACG - Ocrevus





# THANK YOU